Selective Genetics: Filling the gap

Selective Genetics Inc. is looking past the common applications of gene therapy in heritable diseases and cancer, which are mainly systemic in nature, and is developing gene therapies for site-specific disorders and injuries such as dermal ulcers and peripheral nerve injuries.

Formed through the 1998 merger of Matrigen Inc. and Prizm Pharmaceuticals Inc., Selective Genetics incorporates Matrigen's Gene Activated Matrix (GAM) technology and Prizm's Directin fibroblast growth factor (FGF) gene

Read the full 690 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE